Transferring the HIV joint venture to ViiV Healthcare and taking a 10% stake (2012)

How a company without selling power chooses

What was given up was the joint-venture interest, not the intellectual property in the drug. That single point sums up the character of the 2012 restructuring. Shionogi accepted the position of recipient of a royalty averaging in the high teens: the more ViiV sells worldwide, the more Shionogi earns — and the less Shionogi can do to change how fast that happens. A mid-size maker without selling power entrusts selling to a partner that has it, and keeps hold of value at the single point of discovery. The starkness of the judgement shows in the fact that a company which had paid roughly ¥150bn four years earlier for an American sales network decided not to use it for its largest drug.

The arrangement also narrowed the range of what Shionogi could decide for itself. HIV revenue does not appear in its consolidated sales; it arrives only as royalties and dividends. Pricing strategy and the priority given to each market are ViiV's to set. Raising its voting stake to 21.7% in January 2026, making ViiV an equity-method affiliate, appears to be a judgement that it could no longer leave its say over the source of its earnings so thin. What fourteen years as a 10% shareholder taught this company will show in how it handles the relationship from here.